Livaux (Actinidia deliciosa extract)

Livaux is a patented gold kiwifruit extract (Actinidia deliciosa) standardized for its prebiotic polysaccharides and phenolic compounds that selectively feed beneficial gut bacteria. Its primary mechanism involves the slow colonic fermentation of kiwifruit-derived pectin and fiber, which selectively increases populations of Faecalibacterium prausnitzii, a keystone butyrate-producing bacterium linked to gut barrier integrity.

Origin & History

Livaux is a branded prebiotic powder derived from New Zealand gold kiwifruit (Actinidia chinensis var. deliciosa, specifically the non-GMO Zespri SunGold variety). It is produced through a gentle, chemical- and solvent-free lyophilization process that preserves the fruit's natural composition, containing approximately 10% fiber (1/3 soluble pectin, 2/3 insoluble cellulose and hemicelluloses) along with polyphenolic compounds.

Historical & Cultural Context

No historical or traditional medicine use specific to Livaux was identified, as it is a modern branded extract. Gold kiwifruit originates from New Zealand cultivation, but the research provided no references to traditional use in Chinese, Maori, or other cultural medicine systems.

Health Benefits

• Increases bowel movement frequency in healthy individuals (supported by one RCT)
• Promotes growth of beneficial gut bacteria, specifically Faecalibacterium prausnitzii (demonstrated in one comparative study)
• Provides prebiotic fiber that ferments slowly throughout the colon, minimizing gas and bloating (mechanistic evidence)
• Delivers antioxidant polyphenolics including cinnamic acids and total phenolics at 1,100 mg GAE per 100g (compositional analysis)
• Supports overall digestive health through both soluble and insoluble fiber content (based on fiber composition data)

How It Works

Livaux contains a matrix of pectin, hemicellulose, and phenolic compounds from Actinidia deliciosa that resist proximal small intestinal digestion and transit intact to the colon, where they undergo slow anaerobic fermentation. This fermentation selectively stimulates the growth of Faecalibacterium prausnitzii, which produces short-chain fatty acids (SCFAs), primarily butyrate, via butyryl-CoA transferase pathways, fueling colonocytes and supporting tight junction protein expression. The gradual fermentation profile, attributed to the structural complexity of kiwifruit pectin, minimizes rapid gas production compared to rapidly fermenting prebiotics like inulin.

Scientific Research

Clinical evidence for Livaux includes one randomized trial showing 2,400 mg daily increased bowel movements in healthy individuals, and a comparative study demonstrating the same dose increased Faecalibacterium prausnitzii levels in fecal microbiota. While related Actinidia deliciosa extracts have been studied for hepatorenal protection in diabetes models (PMID: 37762060), no additional RCTs or meta-analyses specific to Livaux were identified.

Clinical Summary

A randomized controlled trial (RCT) in healthy adults demonstrated that daily Livaux supplementation significantly increased bowel movement frequency compared to placebo, establishing a foundational clinical signal for its laxation effect. A comparative human study showed that Livaux preferentially increased relative abundance of Faecalibacterium prausnitzii more effectively than psyllium husk, a widely used fiber supplement. Current evidence is limited to a small number of industry-associated studies with modest sample sizes, meaning findings, while promising, require independent replication in larger and more diverse populations. No long-term clinical trials assessing endpoints such as gut barrier function or systemic inflammation biomarkers have been published to date.

Nutritional Profile

{"macronutrients": {"fiber": "Approximately 2.1 grams per 100 grams", "protein": "Approximately 1.1 grams per 100 grams"}, "micronutrients": {"vitamin_C": "Approximately 92.7 mg per 100 grams", "potassium": "Approximately 312 mg per 100 grams", "vitamin_K": "Approximately 40.3 mcg per 100 grams"}, "bioactive_compounds": {"polyphenolics": {"cinnamic_acids": "Present, specific concentration not quantified"}}, "bioavailability_notes": "The fiber content ferments slowly throughout the colon, which may enhance its prebiotic effects while minimizing gas and bloating. The presence of vitamin C enhances the absorption of other nutrients."}

Preparation & Dosage

The clinically studied dosage for Livaux powder is 2,400 mg daily, which provides approximately 240 mg total fiber, 21 mg total phenolics (as gallic acid equivalents), and 18 mg sodium. No other forms or dosage ranges have been studied. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Probiotics, L-glutamine, Slippery elm, Psyllium husk, Digestive enzymes

Safety & Interactions

Livaux is generally well tolerated in healthy adult populations, with its slow-fermentation profile specifically designed to minimize common fiber-related side effects such as bloating, flatulence, and abdominal cramping. No clinically significant drug interactions have been formally documented; however, as a fiber-rich extract, it may theoretically slow gastric emptying and reduce absorption rate of oral medications if taken simultaneously, so spacing administration by at least two hours is a reasonable precaution. Individuals with kiwifruit allergies, which can involve cross-reactivity with latex (latex-fruit syndrome) and birch pollen allergens via Bet v 1 homologs, should avoid Livaux entirely. Safety data in pregnant or breastfeeding women and pediatric populations is insufficient to make formal recommendations.